On October 21, 2019, during UEG week held in Barcelona, ABIVAX has reported Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study.
Information is available at the following link: https://www.abivax.com/investors/ueg-week-2019/
LifeSci Capital Alpha Series:Adam Evertts & David Sherman
goetzpartners securities:Chris Redhead
Kepler Cheuvreux:Damien Choplain